Andelyn Biosciences launches lentiviral vector manufacturing platform for cell therapy development
New platform leverages the established Curator platform methodology to industrialize Lentivirus processes from concept to clinic
15 May 2026Product news
Andelyn Biosciences has launched the LVV Curator® Platform, a standardized lentiviral vector (LVV) manufacturing solution that applies the company’s proven Curator® viral vector platform methodology to industrialize lentiviral processes from concept to clinic.
The new platform is designed to help cell therapy developers transition efficiently from research-grade lentivirus production to GMP manufacturing by providing a predefined, scalable framework that supports speed, quality, and regulatory readiness.
Extending Curator platform pedigree from AAV to LVV
The LVV Curator Platform is the latest addition to Andelyn’s Curator line of viral vector platforms and builds on a methodology that has supported more than 100 adeno-associated virus (AAV) programs across clinical and commercial stages. By extending this commercially validated platform approach into lentiviral vector manufacturing, Andelyn Biosciences brings a structured, repeatable, and scalable framework to early-stage LVV programs.
This platform pedigree is intended to minimize development risk, improve consistency, and deliver operational discipline for cell therapy sponsors seeking to advance LVV-based therapies into the clinic.
Addressing the transition from research-grade to GMP lentiviral manufacturing
A major challenge in cell therapy development is moving from research-grade lentiviral production methods to robust, GMP-compliant manufacturing. The LVV Curator Platform addresses this gap by offering a predefined process architecture that reduces development time and cost while supporting high productivity and purity.
Early partnership model with Optimization-by-Design™
The LVV Curator Platform is built around an early partnership model that incorporates Optimization-by-Design™ principles. Collaborative development begins at project initiation and includes design of experiments (DOE) and data-driven process optimization to establish robust LVV processes more rapidly.
By engaging with sponsors early and applying structured DOE, Andelyn aims to shorten development timelines, refine critical process parameters, and enhance overall process robustness for lentiviral vector manufacturing.
Legacy Curator HEK293 cell line with regulatory acceptance
A key feature of the LVV Curator Platform is the use of Andelyn’s legacy Curator HEK293 cell line, which has clinical experience and established regulatory acceptance. Leveraging this clinically validated HEK293 cell line is intended to streamline development activities and support regulatory confidence for LVV-based cell therapy programs.
This approach allows sponsors to benefit from an existing regulatory track record while building LVV processes that are aligned with expectations for clinical and commercial manufacturing.
Quality-first development aligned with cGMP standards
The LVV Curator Platform is designed with GMP requirements in mind from the outset. Processes are developed under unified cGMP quality systems that are aligned with commercial manufacturing standards, supporting a quality-first approach throughout development.
By embedding quality considerations early, the platform helps ensure that lentiviral vector processes are suitable for clinical manufacturing and can be scaled while maintaining compliance and reproducibility.
Flexible platform methodology for diverse cell therapy programs
While standardized, the LVV Curator Platform maintains flexibility to accommodate client-specific needs. The platform methodology allows for the seamless integration of client-specific cell lines while retaining the standardized process controls and analytical rigor of the Curator framework.
This flexibility enables sponsors to tailor LVV manufacturing to their unique cell therapy constructs and target indications, without sacrificing the benefits of a platform-based approach.
Supporting early-phase programs with a path to scale-up
The LVV Curator Platform is designed primarily to support early-phase cell therapy programs, with a focus on speed, reproducibility, and regulatory readiness. At the same time, the platform maintains a clear path to future scale-up, helping innovators bridge the gap from discovery to clinical manufacturing.
The launch of LVV Curator reinforces Andelyn Biosciences’ commitment to enabling next-generation gene therapies through platform-driven development and manufacturing solutions.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
How does Andelyn Biosciences’ LVV Curator Platform help cell therapy developers transition from research-grade lentivirus production to GMP lentiviral manufacturing?
The LVV Curator® Platform provides a predefined, scalable lentiviral vector (LVV) manufacturing framework that is aligned with cGMP quality systems from the outset. By standardizing process architecture and applying the proven Curator® viral vector platform methodology, it helps developers move efficiently from research-grade lentivirus production to GMP-compliant manufacturing.
This approach is designed to reduce development time and cost while supporting high productivity, high purity, and regulatory readiness for LVV-based cell therapy programs.
What differentiates the LVV Curator Platform from other lentiviral vector manufacturing solutions in terms of platform pedigree and regulatory acceptance?
The LVV Curator Platform extends Andelyn Biosciences’ commercially validated Curator platform, which has supported more than 100 adeno-associated virus (AAV) programs across clinical and commercial stages, into lentiviral vector manufacturing.
A key differentiator is the use of Andelyn’s legacy Curator HEK293 cell line, which has clinical experience and established regulatory acceptance. This platform pedigree and existing regulatory track record are intended to minimize development risk, improve process consistency, and streamline regulatory interactions for sponsors advancing LVV-based gene and cell therapies into the clinic.
How does the LVV Curator Platform’s early partnership model and Optimization-by-Design approach enhance lentiviral vector process development for gene and cell therapy sponsors?
The LVV Curator Platform is built around an early partnership model that incorporates Optimization-by-Design™ principles, engaging sponsors at project initiation. Through collaborative design of experiments (DOE) and data-driven process optimization, Andelyn Biosciences works with clients to establish robust LVV processes more rapidly.
This structured, data-focused approach shortens development timelines, refines critical process parameters, and enhances overall process robustness, while maintaining flexibility to integrate client-specific cell lines and tailor manufacturing to diverse cell therapy constructs and target indications.